Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

Sodium-glucose co-transporter 2 inhibitors (SGLT2is) such as dapagliflozin, canagliflozin, and empagliflozin, are a promising new therapy in the treatment of type 2 diabetes mellitus (T2DM). SGLT2is can effectively reduce hyperglycemia thus improving glycemic control and they offer some beneficial e...

Descripción completa

Detalles Bibliográficos
Autor principal: Saleem, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Diabetes & Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716679/
https://www.ncbi.nlm.nih.gov/pubmed/29226041
http://dx.doi.org/10.7759/cureus.1751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716679/
https://www.ncbi.nlm.nih.gov/pubmed/29226041
http://dx.doi.org/10.7759/cureus.1751

Ejemplares similares